Mary Rinella

Mary Rinella is a Professor in the Department of Medicine-Gastroenterology at the University of Chicago. Her research focuses on metabolic dysfunction-associated steatotic liver disease (MASLD), nonalcoholic fatty liver disease (NAFLD), and their clinical management. She leads studies on therapies like resmetirom and semaglutide, and has contributed to landmark trials such as ESSENCE and MAESTRO-NASH. Her work emphasizes diagnostic improvements, clinical trial design, and global health strategies to address liver disease epidemics. She is a key author of international consensus statements on MASLD nomenclature and guidelines for diagnosis and treatment. Rinella collaborates with multidisciplinary teams and consortia like NailNASH, addressing liver transplantation outcomes, chronic kidney disease risks, and systemic impacts of metabolic dysfunction. Her research bridges molecular mechanisms (e.g., proteomics) with public health initiatives to reduce disparities in liver disease awareness and care.